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Abstract 
Objective. The objective of this study was to examine practices and policies in place for the provision of 
targeted prevention and treatment of cocaine and Amphetamine Type Stimulant (ATS) users in prison in 
nine European countries. Methodology. Across nine European member states (Belgium, the 
Netherlands, Czech Republic, Lithuania, Slovenia, Sweden, Malta, Ireland and Portugal), interviews 
were conducted with ministerial representatives and professionals (i.e. service providers and security 
officials) working in prisons and a total of 16 focus groups with a total of 125 prisoners. Results. The 
use of stimulants in prison is associated with aggression and violence, financial problems, and 
psychological and physical problems in prisoners (depression, anxiety and psychological craving). Both 
security and healthcare staff in prison often feel ill-equipped to deal with stimulant-related problems, 
leading to a lack of equivalence of care for stimulant users in prison, therefore the variety and quality of 
drug services outside is not reflected sufficiently inside prison. There is a need for more specific product 
information and harm reduction material on stimulants, for clear guidelines for the management of acute 
stimulant intoxication and stimulant withdrawal, for structural adjustments to improve potential 
diagnosis of personality and psychiatric disorders, for more non-pharmacological treatment strategies 
and more opportunities for prisoners to engage in purposeful activities. 
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Introduction 
Although it is difficult to identify clear-cut European trends due to a lack of a consistent series of 
surveys, the available data suggest that consumption of stimulants in the general community has 
increased over the last decade. Recent data suggests a stabilisation, however*Europe has become an 
important market for the consumption and distribution of cocaine and cocaine has become a major 
element in the European drug picture (UNODC, 2003a, 2004). In both Western and Eastern Europe, 
drug users reveal a high level of recreational use of cocaine in several social settings. 
 
Similarly, consumption of Amphetamine Type Stimulants (the term refers to both the group of 
amphetamines and the group of ecstasy drugs) has increased over the last two decades. Of the 
amphetamines, amphetamine seems to be by far the most commonly available in Europe, although, 
globally, levels of methamphetamine use are increasing (EMCDDA, 2005; UNODC, 2003b). Among 
younger users, amphetamines were the second most popular substance, but during the 1990s they have 
been overtaken by ecstasy in practically all European countries (EMCDDA, 2004; UNODC, 2003b).  
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For some users, the use of these stimulants can become problematic. During the last decade, cocaine has 
become more commonly identified (compared to opiates and cannabis) as the principal drug used by 
those engaging in drug treatment and accounts for about 10%, predominately by men, of all treatment 
demands across Europe. However, the use of Amphetamine Type Stimulants is still rarely the primary 
reason for attending drug treatment (Klee & Morris, 1994). 
 
It is likely that this upward trend in the use of amphetamines and cocaine in the general population is 
also reflected in prison populations. Although the provision of substitution treatment and other harm 
reduction strategies for prisoners still lags behind the standards of substitution treatment in the 
community, the scope of these interventions is extending gradually across Europe. These strategies, 
however, are mainly targeted at opiate users. For users with stimulant problems there seems to be no 
well-established and widespread pharmacological treatment available, and overall treatment options for 
those with cocaine problems until recently were poorly developed. Nevertheless, new treatment 
responses targeting those with cocaine and/or amphetamine problems are being developed, and new 
measures and initiatives emphasising the prevention and reduction of health-related harm caused by the 
use of cocaine, crack and other stimulants have increased. 
 
The development of services to treat stimulant use in the community raises interesting and until 
recently, under-researched issues, such as the presence of cocaine and Amphetamine Type Stimulant 
users in prisons, the specific problems and risks associated with it and how these are addressed.  
 
This paper presents findings from a study into provisions for treating cocaine and Amphetamine Type 
Stimulant use in prisons, in nine European countries (funded by the European Commission and 
Cranstoun Drug Services/ENDIPP). More specifically, it raises important questions as to whether these 
users have specific needs and whether these needs are being addressed through the existing provisions 
for treatment and harm reduction in European prisons. 
 
Background 
Data regarding the prevalence of stimulant drug use in prisons are limited and it is therefore problematic 
to view this as representative of the actual situation as previous research has shown that the numbers are 
by definition an understatement (Knight et al., 1998; Mason et al., 1997). However, studies have 
highlighted some important issues for consideration such as the different type of drug use prevalent in 
prisons, and the various factors which explain this. The specific type of drug, e.g. opiates, 
amphetamines, will often determine the route of ingestion, such as injecting or smoking. The type of 
drug used prior to imprisonment also impacts on drug user behaviour in the prison and studies have 
shown that prisoners are more likely to continue to use heroin while in prison, compared to either 
cocaine or amphetamines (Keene, 1997; Cope, 2000; Strang et al., 2006). Injecting drug use seems to be 
rare within prisons, and this is often attributed to the lack of needles available (Long et al., 2004). 
However, in both the community and in prison there is not one homogenous subculture of cocaine users 
or amphetamine users. One can find various sophisticated typologies of cocaine users or amphetamine 
users in the international scientific literature (Cohen, 1989; Waldorf et al., 1991; Mugford, 1994; 
Erickson et al., 1994; Decorte & Slock, 2005). 
 
Stimulant use has been identified as more prevalent in pre-trial prisons, or within pre-trial sections of 
prisons compared to sentenced prisons (especially on drug-free wings) which is attributed to the 
presence of more dealers and the absence of urine testing (Mason et al., 1997; Brooke et al., 1998). 
However, studies have also shown that prisoners usually prefer depressant-type drugs in prison as these 
can be used more readily to produce relaxation and to relieve boredom (Swann & James, 1998; Bullock, 
2003; Strang et al., 2006).  
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Users of cocaine and Amphetamine Type Stimulants more often show (or show symptoms of) 
personality disorders or psychiatric problems, such as depression, Attention Deficit Hyperactivity 
Disorder (ADHD), suicidal tendencies, anxiety disorders, psychotic behaviour, borderline personality 
traits (Kleinman et al., 1990; Farrell et al., 2002). At the same time stimulant users seem to conceive 
their drug consumption as non-problematical (Klee & Morris, 1994). The claim for a causal relation 
between the use of stimulants and these behavioural problems is hard to prove, as they may be a direct 
consequence of preexisting disorders or pathologies (such as depression, paranoia, psychosis, auto-
mutilation and suicidal tendencies) (Farrell et al., 2002), and/or influenced by the general condition of 
overcrowding in prisons (MacDonald, 2004). 
 
Other problems related to stimulant use are (psychological) craving, insomnia and physical symptoms 
like heart palpitations, weight loss, exhaustion, hyperthermia, etc. These physical problems are most 
significant and acute in remand prisons, during the first days and sometimes weeks after arrival in 
prison (Mason et al., 1997; Brooke et al., 1998).  
 
In comparison with those who use heroin as their main drug of choice, amphetamine users report greater 
interest in sex and greater frequency of intercourse (Klee, 1993).  Moreover, in many countries 
amphetamine users are less likely to present themselves to treatment services, compared to other users. 
This is related to the perception amongst amphetamine users that treatment services are primarily 
oriented toward opiate users and are usually ill-equipped to deal with amphetamine-related problems 
(Kamieniecki et al., 1998). 
 
The problem is that despite the great deal of effort that has been expended in devising effective 
treatments for cocaine users, there is no consensus regarding effective treatment (WHO, 2000). The 
same is true for amphetamine users (WHO, 2001). However, although there is a lack of consensus on 
effective interventions for stimulant users, some interventions have been found to be more effective than 
others (Kamieniecki et al., 1998; Rigter et al., 2004). Harm reduction campaigns targeting stimulant 
users are sometimes difficult to evaluate, but they seem successful, especially when members of the 
target group are involved in the design of the resources for the campaigns (Kamieniecki et al., 1998).  
 
For the management of acute stimulant intoxication (i.e. management of the toxic complications in 
stimulant users usually in emergency departments of hospitals) guidelines have been devised by 
clinicians with extensive experience (Kamieniecki et al., 1998). There has been extensive research on 
using pharmacological agents to treat stimulant users. Blocking drugs (lithium, ondansetron) have been 
largely unsuccessful in treating stimulant users, and aversive drugs (phenelzyne, tranylcypromine) 
appear to be too dangerous to use. Drugs to decrease the discomfort of stimulant withdrawal and craving 
(such as desipramine, pphenytoin) have demonstrated efficacy in at least some studies, but further 
research is Provisions for stimulant users in prisons needed. The use of replacement drugs in treating 
amphetamine users (such as dexamphetamine) appears potentially promising, but most studies have 
been uncontrolled. 
Controlled trials of the prescription of cocaine have indicated that prescribing cocaine significantly 
reduced relapse to heavy, illicit cocaine use and reduced cravings for the drug 
(Kamieniecki et al., 1998).  
 
The non-pharmacological interventions which have demonstrated the most efficacy in treating stimulant 
users are relapse prevention, cue exposure/response prevention, cognitive-behavioural interventions and 
possibly multifaceted behavioural treatment. Other forms of non-pharmacological interventions have 
not been evaluated properly (Rigter et al., 2004). 
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Methodology 
The general objective of this study was to examine practices and policies in place for the provision of 
targeted prevention and treatment of cocaine and Amphetamine Type Stimulant users in prison in nine 
European countries. The specific objectives of this study were (a) to undertake a review of the national 
strategies to address Amphetamine Type Stimulant use for detainees; (b) to examine in detail the 
policies and the implementation of services in two sample institutions which address the needs of 
Amphetamine Type Stimulant users; (c) to establish the needs of Amphetamine Type Stimulant users in 
the two sample institutions; (d) to identify gaps in and barriers to accessing service provision among 
Amphetamine Type Stimulant users in the two sample institutions; and (e) to promote awareness of the 
initiatives operating in the area of Amphetamine Type Stimulant use for prisoners. 
 
The study was based on a similar research design as previous studied commissioned by Cranstoun Drug 
Services (for example Sto¨ver et al., 2004; MacDonald, 2004; Sto¨ver, 2001), using qualitative methods 
such as guided interviews and focus groups. Qualitative methods have proven to be suitable for public 
health studies and complex contexts as well as for charting the differing views of those involved. The 
choice of a qualitative approach reflects the fact that the drug-related health strategies (especially harm 
reduction measures) in prisons are a controversial issue in many countries and require a sensitive 
approach. Indeed, qualitative methods are a relevant and useful research tool to reach a deeper 
understanding of the phenomenon of drug-related services in prisons, as well as to evaluate it from the 
perspective of those involved in it. 
 
This study is therefore not comparative or representative, but explorative. The researchers were not 
concerned with testing pre-existing hypotheses. Instead, the focus was on gaining knowledge, 
experiences, attitudes and perceptions of different groups involved in specific health interventions. 
Using qualitative methods enabled the researchers to better understand participants’ experiences, views 
and opinions and present findings within the context of the settings of the research and the issues raised 
by it.  
 
The research took place in nine European countries: Belgium, the Netherlands, Czech Republic, 
Lithuania, Slovenia, Sweden, Malta, Ireland and Portugal. In each of these countries, national 
facilitators were identified through the ENDIPP-network. These country co-ordinators, usually working 
in the national prison service, played a key role in the process of this research. They assisted in 
collection and, if necessary, translation of relevant documents, in identification of experts and potential 
interviewees, in the selection of two sample prisons for a field visit, and in the general organisation of 
the fieldwork.  
 
Between 2005 and 2006 two sample prisons were visited in each country, except Malta. During each 
field visit, guided interviews were conducted with ministerial and nongovernmental organisation 
representatives, and with professionals working in prison from health and security. These professionals 
included the drug treatment team (i.e. medical doctor, psychiatrist and nurse), the psycho-social team 
(i.e. psychologist, social worker, pedagogue, educator), guards, management team and the governor 
and/or deputy governor. Participants were asked open-ended questions, preferably in face-to-face 
interviews. On two occasions, some participants were interviewed together, according to available 
resources and local organisation. Each interview lasted approximately 45-75 minutes. 
 
In each prison, prisoners with a history of cocaine or Amphetamine Type Stimulant use and/or 
experiences with drug treatment while in prison and/or in the community were invited to take part in a 
focus group interview. In addition, a professional involved in treatment or services for drug users, 
identified by the ENDIPP national facilitators, organised the interviews according to the researchers’ 
requirements, which were communicated prior to the field visit. Prisoners were interviewed in a neutral 
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room within the prison and in the sole presence of the researcher. Further to prisoners’ consent, the 
focus group interview was tape-recorded for data analysis purpose, and remained in the sole possession 
of the researcher. Open-ended questions were asked in focus groups with prisoners. Focus groups, 
which included on average 7.8 prisoners per group, lasted approximately 90 minutes. In total, 16 focus 
groups in 16 prisons across 8 countries were conducted, reaching a total number of 125 prisoners.  
 
Participants were interviewed in their native language either directly by the researchers (in Belgium and 
the Netherlands, because they spoke the language) or via an interpreter (in Ireland, Slovenia, Portugal, 
Sweden, Czech Republic and Lithuania). Participants were briefed and debriefed on the research goals 
and ethical issues. Their participation was voluntary, confidential and anonymous. 
 
Due to time and resource constraints, data on Malta were collected through distant data collection 
techniques. These include review of the available data on Malta in databases such as those produced by 
the EMCDDA, and library and internet searches. The location of key stakeholders and staff members 
from relevant external organisations was also established via the Internet or obtained through 
colleagues. On several occasions these participants were contacted (by e-mail, by telephone, by fax) and 
invited to supply information on relevant research questions by e-mail or fax. Distant data collection 
techniques have obvious disadvantages, as they can be impersonal and time consuming and exclude the 
views of prisoners on service provision, as they cannot be contacted in the same way as staff and other 
professionals. Therefore, these are not included within the data from the Maltese Correctional Facility. 
 
The qualitative data collected through the interviews and focus groups were analysed using a content 
analysis method, which generated themes and categories. Because the results are primarily based on 
field visits conducted in a limited number of prisons, with a limited number of participants, the findings 
are not representative.  
 
Limitations of the present study 
It is evident that this study only offers snapshots of the services provided for cocaine and ATS users in 
European prisons. Considering the heterogeneity of treatment programmes across European prisons, the 
findings provide a limited basis for comparison. Moreover, the Provisions for stimulant users in prisons 
descriptions obtained during the field visits do not generate a generalised picture of a country. Instead, 
they reflect the subjective experience of some individuals involved with drug-related measures and 
reflect some specific practices in different prisons and countries.  
 
A qualitative design, such as the one used in this study, does not produce reliable, comparable and 
meaningful hard statistics or a quantitative analysis of the prevalence of drug users in a particular 
prison, the prevalence of different types of substances (such as stimulants) in that prison, and*to a lesser 
extent*the patterns of use of different substances within that prison setting. 
 
Results 
Prevalence of cocaine and Amphetamine Type Stimulant users in prison 
Most interviewees in our study report a general increase of stimulants use in prisons. In some countries, 
such as the Czech Republic and Sweden, the use of Amphetamine Type Stimulants is not a very recent 
phenomenon, but in other countries indirect indicators of drug use in prison already seem to reflect the 
general upward trend of stimulant use in the community. Using or trafficking cocaine or Amphetamine 
Type Stimulants is an illegal act in all of the countries in this study (and by extension in all European 
countries), and thus subject to criminal justice sanctions.  
Both in general society and in a prison setting, people tend to conceal their drug use. Under these 
conditions, admitting and talking about drug use to other people is often hindered by a general sense of 
Please use the following citation: Decorte T (2007) Problems, needs and service provision related to stimulant use in European 
prisons, (Author postprint) in International Journal of Prisoner Health, 3(1): 29-42, [Accessed: (date) from 
www.drugsandalcohol.ie]   
 
6
embarrassment, as using drugs is perceived by many as a sign of personal weakness, psychological 
malfunctioning or even a disease, both outside and inside the prison. Moreover, admitting or talking 
about drug use often implies that security staff, medical or social staff will initiate a range of strategies 
with the intent of controlling, changing or adjusting the individual’s behaviour. When a person is not 
ready or not willing to allow others to interfere or help him/her with drug-related issues, he/she will 
prefer to keep the use of any (illegal) drug hidden. As one prisoner noted ‘‘[. . .] there are a lot of 
cocaine users here . . . who aren’t here [i.e. in the focus group] because they fear supervision’’ (Prisoner, 
Hasselt prison, Belgium). 
 
Even if the number of seizures of stimulants are low in prison and self-reports of cocaine use by 
prisoners are rare, this should not automatically lead to the assumption that actual use of these 
substances is low. Some of the people interviewed claimed that there was no need for concern, as the 
available indicators did not show Stimulant use:  
 
You do not see stimulant use. Cocaine is a big problem on the outside, but does not 
seem to have crossed into prison [. . .] They may have used it in the past, maybe in the 
community but they do not in prison. Are the prisoners saying that they use in the 
prison? (Medical staff, Mountjoy prison, Ireland). 
 
We must add that concepts or categories such as ‘cocaine users’ and ‘speed users’ partly lose their 
usefulness, as in most countries, our respondents have indicated that polydrug use is a widespread 
phenomenon. Incidences of combined use of opiates (heroin or methadone) and cocaine, of alcohol and 
opiates or cocaine, of amphetamines and other drugs and combinations with cannabis and legal 
prescription drugs were reported in all countries involved in this study. 
 
Routes of ingestion 
Cocaine and Amphetamine Type Stimulants show a great diversity in the ways in which they can be 
taken. In the general population, snorting is the most widespread method. In general, most respondents 
claimed that injecting stimulants in European prisons is rare. This view was shared by most of the 
representatives of the National Prison Administrations of the countries visited and by several staff 
members in several of the sample prisons. The two most frequently heard explanations for this are that 
there are few needles available in prison and that most prisoners seem to be aware of the risks associated 
with intravenous use of drugs (such as the contraction of blood-borne viruses). According to these 
respondents, the fact that seizures of needles in prison are rare is proof of the low prevalence of 
intravenous use.  The fact that cocaine and Amphetamine Type Stimulants can be snorted, swallowed or 
in some cases inhaled (‘chasing the dragon’ or ‘freebasing’), seems to be perceived by prisoners as 
‘safer’, even though there are some risks associated with these methods:  
  
I did a line together with my cell mate. We watched football and had a nice evening. 
It felt like an evening out. People think that snorting coke brings a milder crash than 
smoking crack. But I don’t like snorting. I always smoke cocaine. And when I got 
raw cocaine I make base by myself. Of course ammonia (to make base coke) is hard 
to get inside*but then I just took urine*it’s working too. We are real professors in this 
field (prisoner, PI Vught, The Netherlands). 
 
This is confirmed by some prisoners, who claim that needles are hard to get and that, among prisoners, 
intravenous drug use is perceived as marginal. If inmates do inject, they tend to do it alone and secretly, 
or within a very small group of fellow intravenous users. However, there are indications that in some 
prisons injecting drugs (including cocaine and Amphetamine Type Stimulants) is on the rise, or already 
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widespread, according to prisoners. For some, there is an economic aspect to this route of ingestion: if 
you inject drugs you can get more of an effect than if you inhale or sniff it. 
 
Factors influencing stimulant use in prison 
The use of stimulants in prison is influenced by many factors. Of course, there may be a relationship 
between drug use within prison and the type of drug used prior to imprisonment, but this is not always 
an absolute relationship. Our findings suggest that changes in the drug-taking behaviour of drug users 
after imprisonment vary according to the type of drug being taken. Prisoners are more likely to continue 
to use heroin while in prison, compared to either cocaine or amphetamines. 
 
An obvious factor which influences cocaine or Amphetamine Type Stimulant use in prison is 
availability (or the lack of availability). There is no reason why the smuggling of stimulant drugs into 
prisons would be more difficult than that of heroin. According to prisoners, availability of cocaine and 
Amphetamine Type Stimulants is higher in remand prisons or pre-trial sections than in other sections 
due to the presence of more dealers and the absence of urine testing and lower in drug-free wings or 
treatment sections. 
 
Clearly, availability of stimulants in prison is itself influenced strongly by demand factors, such as the 
high price. Cocaine is, in most countries, an expensive drug and price levels in prison are generally 
higher than in society, as suppliers charge the costs and risks of smuggling to the consumer. Although 
the objective price level of a substance is an Provisions for stimulant users in prisons important demand 
factor, it must be stressed that there is of course an individual element in the perception of prisoners, 
according to their financial situation. What is not affordable to some prisoners, may well be affordable 
to others. Therefore, some prisoners may have sufficient resources to pay for cocaine in prison, and 
some may not. The high price of stimulants such as cocaine may also cause serious financial problems 
in prison after a while, in terms of debts to suppliers:  
 
I see people in prison, they have a lot of money [in] the beginning and they use 
stimulants [. . .]. But they spend their money very soon and then there is a crisis, and 
they sell everything, the computer, clothes (ex-prisoner of Ljubljana prison in 
Slovenia).  
 
Another important demand factor influencing the availability of stimulants in prison is their 
inappropriateness for a prison environment. As noted by one member of the focus group, ‘‘Heroin is the 
prison drug. [. . .] What is the point of being out of your head and locked in your cell? You would go 
mad and out of your head on your own’’ (Prisoner, Dochas Centre, Ireland). 
 
Our interviews suggest that prisoners usually prefer depressant-type drugs in prison as these can be used 
more readily to produce relaxation and to relieve boredom. Many outside users of stimulants become 
users of opiates, cannabis or depressant prescription drugs in prison. However, some prisoners stated 
they would use stimulants in prison, as they ‘make time go faster’, they are less easily detected 
(compared to cannabis), they reduce hunger, and can counter and mask the effects of opiates.  
 
Availability of substances in prison in some countries may also be significantly lower in institutions for 
female prisoners. According to some respondents, this is related to ‘better’ drug supply networks in 
male prisons and the fact that women generally chose different coping strategies to adapt to prison life.  
 
Many of our interviewees contend that the presence of activities, such as employment, training facilities, 
fitness and other leisure activities and the presence of therapeutic programmes (in drug-free zones), can 
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act as useful alternatives to using drugs. Prisoners who work, attend educational training, or have 
sufficient access to leisure facilities tend to be less interested in using drugs. 
 
Profiles of stimulant users in prison 
Some of our respondents suggested that stimulant users in prison tend to be younger people, with a 
larger proportion of women. As to the socio-economic backgrounds, perceptions vary significantly from 
country to country. Stimulant users are also more likely to display symptoms of personality disorders or 
psychiatric problems, but are also less likely to view their drug use as problematic.  
 
Problems and risks related to stimulant use in prison 
The question as to whether the use of stimulants in prisons represents specific problems and risks is not 
easy to answer. Many factors related to the prison setting itself intensify feelings of stress, anxiety and 
paranoia in most inmates, whether they use drugs or not. Moreover, the prison population contains a 
higher proportion of people with psychiatric problems and or personality disorders, irrespective of their 
substance use.  
 
The use of stimulants in prison is often associated with higher levels of aggression, violence and 
bullying, and can result in more unpredictable behaviour. The increase in violence may also be related 
to conflicts between prisoners, related to the drug trade and bargaining and financial disputes 
(irrespective of the type of drug):  
 
The withdrawal symptoms of heroin are more physical and it’s possible to use 
medication to take care of that. I am a pure pervitin user. The withdrawal with 
amphetamines is more mental or psychic, anxiety or paranoia (Prisoner, Rynovice 
Prison, Czech Republic)  
 
Other problems related to stimulant use are (psychological) craving, insomnia, and physical symptoms 
like heart palpitations, weight loss, exhaustion, hyperthermia, etc. These physical problems are most 
significant and acute in remand prisons, during the first days and sometimes weeks after arrival in 
prison. Several interviewees indicated that these symptoms might initially be very intensive and 
problematic and require close follow-up and assistance from staff, but that these symptoms generally 
wear off as the prisoner goes through withdrawal, as the body gains weight and recovers from 
exhaustion. 
 
In our interviews with prison staff, a high prevalence of psychological symptoms, such as depression, 
anxiety, mood swings, paranoia and hallucinations was related to frequent amphetamine use and use by 
injection. A considerable proportion of amphetamine users are clinically depressed (and probably a 
considerable proportion of prisoners in general), and the use of stimulants aggravates this problem.  
 
Within prison systems, whose key aims are control, calmness and order, the typical nervous and 
hyperactive behaviour of stimulant users is often seen as a difficult aspect to manage. Some respondents 
claimed that this is one of the reasons why stimulant users seem to end up much more frequently in 
disciplinary or isolation cells.  
 
In addition, many stimulant users in prison do not see themselves as having a drug problem, in that they 
do not identify themselves with a subculture of drug users and, therefore, often refuse help. For security 
staff, it was found that specifically identifying stimulant users was difficult and among medical and 
treatment staff, the main problem identified was that they lack experience and guidelines in handling 
stimulant users: 
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The ones who use opiates, they practically are sure that they have a great risk of 
becoming addicts. The ones who use amphetamine somehow believe that it’s not such a 
problematic thing and they won’t get addicted (psychologist, Marijampole prison, 
Lithuania). 
 
A risk regularly associated with amphetamine use in the international literature, but oddly enough not 
mentioned in any of our interviews, is the effects of stimulants upon sexual activity and a sex life 
enhanced by these drugs. A large proportion of these users also engage in unprotected sex, increasing 
the risk of HIV infection, and infection with sexually transmittable diseases. The fact that this issue was 
never mentioned during our fieldwork may indicate several things. First of all, it may illustrate the taboo 
on sexual activity within prisons. Second, it may illustrate the lack of awareness among staff and 
prisoners related to the links between stimulant use and sexual risk behaviour. Third, there is very little 
information on the effect of stimulant use in a prison setting on sexual interest and sexual activity. For 
some users, the prison setting itself may decrease the interest in sex, but not the interest in drugs. 
 
Needs of prisoners and staff regarding stimulant use 
First of all, there is a need for more specific information on stimulants, both for security and treatment 
staff, in order to help them recognise use of these substances among prisoners and address associated 
problems. There is also a need for specific, non-judgmental and useful harm reduction material for 
prisoners*for example, to increase knowledge regarding needle cleaning procedures, methods of 
minimising ‘comedown’, managing symptoms of withdrawal, the importance of sleep and good diet, the 
need to avoid dehydration, the dangers of combined use or polydrug use and measures to prevent 
overdoses, particularly on release from prison. 
 
Both prison hospital staff and medical staff in the sample prisons highlighted the need for guidelines 
about the management of acute amphetamine and cocaine intoxication, based on literature and the 
experience of leading clinicians and healthcare services in the field.  
 
Many of the physical and psychological problems reported above are most acute when these users arrive 
in prison (in remand prisons for example) and when these users go through some weeks of 
detoxification. Medical and healthcare staff should be provided with detailed guidelines for the 
management of stimulant withdrawal, as this can be very different to that of opiate withdrawal. This 
should include guidelines regarding the use of benzodiazepines and antipsychotic agents, but the use of 
these medications on their own is insufficient to deal with stimulant withdrawal. Strategies other than 
pharmacotherapy, such as organising support, non-pharmacological means of coping with cravings, tips 
to improve sleep, relaxation techniques, coping with mood swings, aches and pains, eating properly, 
concentrating only on the immediate future and so on, may each work to some extent:  
 
There’s no help for cocaine users; if you’re a heroin user, you get methadone and then 
you’re ok, you’re minding your own business but if you’re cocaine user, you can’t get 
anything because they don’t know what to give you. They don’t even give sedatives 
(Prisoners, Ljubljana prison, Slovenia). 
 
Many of our respondents complained about the lack of a substitution therapy similar to methadone for 
opiate users. Pharmacological agents (such as blocking drugs, aversive drugs and replacement drugs) 
have been used in the past to treat stimulant users, but the efficacy of these products is controversial (see 
below). 
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Some stimulant users in prison are ‘walking bombs’ in the sense that they have very complex 
psychiatric problems, which are sometimes not diagnosed. There is a need to make structural 
adjustments to improve potential diagnosis of personality and psychiatric disorders and to provide 
adjusted guidance in specific detention settings or specialised prison sections. 
 
However, the most commonly identified gap in provisions for stimulant users is the need for strategies 
that surpass the basic medical or product-oriented approach, including psychological support. Many 
prisoners expressed that this was a greater need compared to simply providing more medication, in 
order to address the psychological dependence, and the psychosocial aspects of their drug-taking 
behaviour. There is also a need for staff to be better trained in recognising stimulant-related problems 
and in more appropriate ways of reacting towards the problems mentioned earlier. 
 
Finally, many prisoners use drugs to relieve boredom and to kill time. There is clearly a need for a more 
meaningful prison regime, in which prisoners are kept busy, through work, training, education and 
leisure activities. The views of staff and prisoners for a more meaningful imprisonment and for more 
psychosocial assistance (rather than product-oriented strategies) also demonstrates the in-
appropriateness of imprisoning problematic drug users, as within this setting, the range of strategies 
needed to treat drug use are not widely available. 
 
Targeted interventions in prison 
In this study almost no targeted interventions towards stimulant users in prison were found. In several 
countries, staff members and representatives suggested the issues of cocaine use or amphetamine use 
had come up in group sessions or in individual counselling, or in information sessions by external 
organisations. However, when these interviewees were asked for more details on the nature and the 
extent of these sessions, no evidence for a systematic, guided approach towards stimulant users was 
found. None of the prisoners acknowledged the existence of targeted interventions towards stimulant 
users. In those countries with explicit national drug policies in prison, no differentiation is made 
between stimulants and opiates. And even in those countries that have a ‘tradition’ of higher prevalence 
of amphetamine use, no targeted or very specific interventions were uncovered.  
 
A claim made by several respondents to explain the lack of targeted interventions towards stimulant 
users was that there are no targeted interventions in the community either. In many countries this seems 
an acceptable argument, as most provisions and services offered by local NGOs and treatment centres 
are not differentiated for opiate users and stimulants users, or (in the case of substitution treatment for 
example) mainly targeting opiate users. 
 
Conclusions and recommendations 
The use of cocaine and Amphetamine Type Stimulants in prison does raise some concerns, even if the 
available indicators do not show an increase. Their use is associated with aggression and violence, 
financial problems and psychological and physical problems in prisoners. Additionally, prison staff 
(both medical and security staff) often feel ill-equipped to deal with stimulant-related problems. These 
conditions are detrimental to the health of these prisoners and increase the risk of HIV transmission, 
encourage drug use in response to boredom or stress and increase stress among inmates, which 
negatively affects their mental health, or exacerbates pre-existing mental health problems. Both in the 
community and in prison there is not one homogenous subculture of cocaine users or amphetamine 
users. One can find various sophisticated typologies of cocaine users or amphetamine users in the 
international scientific literature (Cohen, 1989; Waldorf et al., 1991; Mugford, 1994; Erickson et al., 
1994; Decorte & Slock, 2005), and from our interviews, it became clear that one can find various types 
of users in prison as well. 
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The reasons given for the lack of targeted efforts for stimulant users were related to barriers and 
problems that hinder the provision of services and harm reduction strategies in prison in general. Many 
of these barriers and problems have been identified in several previous studies, such as the lack of 
evidence-based policies, the one-sided and unilateral focus on supply reduction, budget constraints, the 
over-incarceration of drug users, the general negative attitude towards drug users, staff shortage, 
qualifications and training of security staff and healthcare staff, the need for multidisciplinary action, the 
suspicion towards and therefore lack of structural agreements with outside drug service providers 
(NGOs) and overcrowding within prisons (MacDonald, 2004). Another factor hampering the 
development of targeted interventions towards stimulant users is that much of the intervention literature 
for stimulant users has come from the United States and has primarily involved cocaine users. However, 
many types of interventions have been conducted with stimulant users, including preventive 
interventions and the provision of harm reduction information, the management of acute stimulant 
intoxication, withdrawal management, pharmacological and non-pharmacological treatments and 
interventions for stimulant users with co-morbid psychiatric disorders.  
 
The principle of equivalence means that the healthcare measures (medical, psychiatric and 
psychosocial) successfully proven and applied outside prison should also be applied inside prison. 
Prisoners are entitled, without discrimination, to a standard of healthcare equivalent to that available in 
the outside community, including preventive measures. This principle of equivalence is fundamental to 
the promotion of human rights and best health practice within prisons, and is supported by international 
guidelines on prison health and prisoners’ rights (by the United Nations, the World Health Organization 
and UNAIDS), as well as national prison policy and legislation in many countries. 
 
With regard to support for drug-using inmates, and especially cocaine- and Amphetamine Type 
Stimulant-using inmates, and to those with underlying personality disorders and psychiatric problems, 
the principle of equivalence is still wishful thinking. Differentiation and quality of drug services outside 
is not reflected sufficiently inside prison. General barriers to implementation of effective prison 
healthcare strategies have been described and identified a long time ago and in various other studies. It 
is clear that a lot needs to be done to make imprisonment more than a punitive institution. If 
reintegration of prisoners in general, and drug users in prison in particular, is truly an objective and a 
function of our prison systems, then these barriers and problems in organising healthcare in prison need 
to be tackled in a much more convincing way. 
 
In our interviews with prison staff a high prevalence of psychological symptoms, such as depression, 
anxiety, mood swings, paranoia and hallucinations was related to frequent amphetamine use, and use by 
injection (see also: Louie et al., 1989; Kleinman et al., 1990; 
Hall & Hando, 1994a,b). A considerable proportion of amphetamine users are clinically depressed (and 
probably a considerable proportion of prisoners in general), and the use of stimulants aggravates this 
problem. Some prisoners have experiences of psychological symptoms prior to their initiation to 
stimulant use, but most of these symptoms increase in prevalence after the onset of stimulant use 
(Farrell et al., 2002). 
 
In many countries, a significant percentage of the prison population is comprised of individuals who are 
convicted of offences directly related to their own drug use (i.e. those incarcerated for the possession of 
small amounts of drugs for personal use, those convicted of petty crimes specifically to support drug 
habits). The incarceration of significant numbers of drug users increases the likelihood of drug use 
inside prisons and, therefore, an increase in unsafe injecting practices and the risk of HIV-transmission. 
Drug users do not belong in prison, and prison settings are not the ideal setting for drug treatment. 
Action should be taken to reduce prison populations and prison overcrowding, as an integral component 
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of a comprehensive strategy to improve prison healthcare towards drug users (including stimulant 
users). Legislative and policy reforms should be pursued to change criminal law and penalties with the 
objective of reducing the criminalisation of non-violent drug offences and significantly reducing the use 
of incarceration for non-violent drug users. 
 
In order to reduce the number of drug users sent to prison, the overall prison population and the levels of 
prison overcrowding, alternatives to prison and non-custodial diversions for people convicted of 
offences related to drug use should be developed. If imprisonment itself cannot be avoided, then 
treatment and preventive steps have to be taken from the first day of imprisonment (Stöver, 2001). That 
includes comprehensive medical care of withdrawal symptoms from stimulant use, as well as access to 
health and social workers both from inside prison and from community services in order to define 
individual problems and disorders.  
 
With regard to medical treatment, increased efforts need to be undertaken in prisons to ensure that 
(stimulant) using prisoners receive care, support and treatment equivalent to that available in the 
community. Prisoners suffering from withdrawal symptoms (among others from stimulants) should 
have equal access to narcotics routinely given for pain relief, reduction of anxiety and paranoia to 
patients outside. Prisoners should be allowed equal access to investigational drugs and nonconventional 
therapies for stimulant users outside. There is also a need to address problems associated with dual 
diagnosis, i.e. drug users who are also identified as having mental health problems, through the 
development of adjusted guidance in specialised detention settings.  
 
Inmates should have access to voluntary treatment options that exist in the community, such as relapse 
prevention, cue exposure/response prevention, cognitive behavioural interventions and multifaceted 
behavioural treatment. The claim made by Stoöver (2001) is still relevant, in that correctional healthcare 
needs to evolve from a reactive sick-call system to a proactive system emphasising early detection of 
personality disorders and psychiatric problems, health promotion among drug users, and prevention.  
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